SLX9 and osteosarcoma: Figure 2F–J shows that the five-year survival rate of osteosarcoma cases with high expression of ST3GAL4, TRIM8, FAM207A, TRPS1, and STC2 was lower than that of low-expressing cases (P < 0.05).